Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]

被引:0
|
作者
Fu, Liang [1 ]
Xiong, Juan [2 ]
Wang, Haibo [3 ]
Zhang, Peize [1 ]
Yang, Qianting [1 ]
Cai, Yi [4 ]
Wang, Wenfei [1 ,4 ]
Sun, Feng [5 ]
Zhang, Xilin [6 ]
Wang, Zhaoqin [1 ]
Chen, Xinchun [4 ]
Zhang, Wenhong [5 ]
Deng, Guofang [1 ]
机构
[1] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis Shenzhen, Div Pulm Dis Dept 2,Shenzhen Clin Res Ctr TB, 29 Bulan Rd, Shenzhen 518112, Peoples R China
[2] Shenzhen Univ, Hlth Sci Ctr, 3688 Nanhai Ave, Shenzhen 518060, Peoples R China
[3] Peking Univ First Hosp, Peking Univ Clin Res Inst, Xueyuan Rd 38, Beijing 100191, Peoples R China
[4] Shenzhen Univ, Dept Pathogen Biol, Guangdong Key Lab Reg Immun & Dis, Sch Med, 1066 Xueyuan Ave, Shenzhen 518060, Peoples R China
[5] Fudan Univ, Huashan Hosp, Natl Med Ctr Infect Dis, Dept Infect Dis,Shanghai Key Lab Infectious Dis &, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China
[6] Fourth Peoples Hosp Foshan, TB Prevent & Control Dept, 106 Jinlannan Rd, Foshan 528000, Peoples R China
关键词
Multidrug-resistant; Tuberculosis; Efficacy; Safety; Trial; OUTCOMES;
D O I
10.1186/s12879-023-08644-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
IntroductionThe urgent need for new treatments for multidrug-resistant tuberculosis (MDR-TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is evident. However, the classic randomized controlled trial (RCT) approach faces ethical and practical constraints, making alternative research designs and treatment strategies necessary, such as single-arm trials and host-directed therapies (HDTs).MethodsOur study adopts a randomized withdrawal trial design for MDR-TB to maximize resource allocation and better mimic real-world conditions. Patients' treatment regimens are initially based on drug resistance profiles and patient's preference, and later, treatment-responsive cases are randomized to different treatment durations. Alongside, a single-arm trial is being conducted to evaluate the potential of sulfasalazine (SASP) as an HDT for pre-XDR-TB, as well as another short-course regimen without HDT for pre-XDR-TB. Both approaches account for the limitations in second-line anti-TB drug resistance testing in various regions.DiscussionAlthough our study designs may lack the internal validity commonly associated with RCTs, they offer advantages in external validity, feasibility, and ethical appropriateness. These designs align with real-world clinical settings and also open doors for exploring alternative treatments like SASP for tackling drug-resistant TB forms. Ultimately, our research aims to strike a balance between scientific rigor and practical utility, offering valuable insights into treating MDR-TB and pre-XDR-TB in a challenging global health landscape. In summary, our study employs innovative trial designs and treatment strategies to address the complexities of treating drug-resistant TB, fulfilling a critical gap between ideal clinical trials and the reality of constrained resources and ethical considerations.Trail registrationChictr.org.cn, ChiCTR2100045930. Registered on April 29, 2021.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
    Souleymane, Mahamadou Bassirou
    Decroo, Tom
    Soumana, Alphazazi
    Lawan, Ibrahim Maman
    Gagara-Issoufou, Assiatou
    Halidou-Moussa, Souleymane
    Ortuno-Gutierrez, Nimer
    Adehossi, Eric
    Mamadou, Saidou
    Van Deun, Armand
    Piubello, Alberto
    TRIALS, 2022, 23 (01)
  • [32] Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol
    Hosogaya, Naoki
    Takazono, Takahiro
    Ota, Kenji
    Kiya, Rieko
    Shirai, Yumi
    Kawasaki, Rina
    Yano, Hiroshi
    Morimoto, Shinpei
    Nakao, Rumiko
    Kanamaru, Yumiko
    Yoshino, Yukari
    Ishikawa, Yasuyuki
    Fukushima, Chizu
    Yamamoto, Hiroshi
    Izumikawa, Koichi
    Yanagihara, Katsunori
    Mukae, Hiroshi
    MEDICINE, 2023, 102 (08)
  • [33] A Multicenter Single-Arm Objective Performance Criteria Trial to Determine the Efficacy and Safety of High-Frequency Irreversible Electroporation as Primary Treatment for Localized Prostate Cancer: A Study Protocol
    He, Bi-Ming
    Xue, Wei
    Yan, Wei-Gang
    Yin, Lei
    Dong, Bai-Jun
    Zhou, Zhi-En
    Lin, Heng-Zhi
    Zhou, Yi
    Wang, Yan-Qing
    Shi, Zhen-Kai
    Zhou, Hai
    Wang, Shuai-Dong
    Ren, Shan-Cheng
    Gao, Xu
    Wang, Lin-hui
    Xu, Chuan-Liang
    Wang, Hai-Feng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
    Su, Hao
    Shang, Xiao
    Liu, Hongruo
    Wang, Yutong
    Yu, Yang
    Xu, Yanhua
    Jiang, Kui
    Feng, Fengzhi
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2025, 17 : 325 - 333
  • [35] TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
    Catherine Berry
    Philipp du Cros
    Katherine Fielding
    Suzanne Gajewski
    Emil Kazounis
    Timothy D. McHugh
    Corinne Merle
    Ilaria Motta
    David A. J. Moore
    Bern-Thomas Nyang’wa
    Trials, 23
  • [36] EFFICACY OF TWO AYURVEDA DRUG REGIMENS FOR UTERINE FIBROIDS, A RANDOMIZED, SINGLE BLIND, THREE-ARM, CLINICAL TRIAL-STUDY PROTOCOL
    Karunagoda, Kaumadi
    Perera, Pathirage Kamal
    Senanayake, Hemantha
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2019, 10 (03): : 1366 - 1371
  • [37] Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
    Miyake, Hideaki
    Kakei, Yasumasa
    Nakano, Yuzo
    Terakawa, Tomoaki
    Miyakoda, Keiko
    Harada, Kenichi
    Fujisawa, Masato
    BMJ OPEN, 2023, 13 (03):
  • [38] TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
    Berry, Catherine
    du Cros, Philipp
    Fielding, Katherine
    Gajewski, Suzanne
    Kazounis, Emil
    McHugh, Timothy D.
    Merle, Corinne
    Motta, Ilaria
    Moore, David A. J.
    Nyang'wa, Bern-Thomas
    TRIALS, 2022, 23 (01)
  • [39] Clinical efficacy and safety of nivolumab in malignant non-pleural mesothelioma: A multicenter, open-label, single-arm, Japanese phase II trial (VIOLA) protocol
    Kuribayashi, Kozo
    Igeta, Masataka
    Daimon, Takashi
    Maede, Ibu
    Suna, Shinichiro
    Okamoto, Rika
    Kijima, Takashi
    ONCOLOGY, 2023, 101 (04) : 257 - 261
  • [40] Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
    Lee, Myungsun
    Mok, Jeongha
    Kim, Deog Kyeom
    Shim, Tae Sun
    Koh, Won-Jung
    Jeon, Doosoo
    Lee, Taehoon
    Lee, Seung Heon
    Kim, Ju Sang
    Park, Jae Seuk
    Lee, Ji Yeon
    Kim, Song Yee
    Lee, Jae Ho
    Jo, Kyung-Wook
    Jhun, Byung Woo
    Kang, Young Ae
    Ahn, Joong Hyun
    Kim, Chang-Ki
    Shin, Soyoun
    Song, Taeksun
    Shin, Sung Jae
    Kim, Young Ran
    Ahn, Heejung
    Hahn, Seokyung
    Won, Ho Jeong
    Jang, Ji Yeon
    Cho, Sang Nae
    Yim, Jae-Joon
    TRIALS, 2019, 20 (1)